Discounted Cash Flow (DCF) Analysis Unlevered
Global Blood Therapeutics, Inc. (GBT)
$68.49
+0.01 (+0.01%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBITDA (%) | ||||||||||
| EBIT | - | - | - | - | - | - | - | - | - | - |
| EBIT (%) | ||||||||||
| Depreciation | - | - | - | - | - | - | - | - | - | - |
| Depreciation (%) |
Balance Sheet Data
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Total Cash | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Cash (%) | ||||||||||
| Account Receivables | - | - | - | - | - | - | - | - | - | - |
| Account Receivables (%) | ||||||||||
| Inventories | - | - | - | - | - | - | - | - | - | - |
| Inventories (%) | ||||||||||
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable (%) | ||||||||||
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) |
Weighted Average Cost Of Capital
| Share price | $ 68.49 |
|---|---|
| Beta | 0.463 |
| Diluted Shares Outstanding | 62.93 |
| Cost of Debt | |
| Tax Rate | -0.16 |
| After-tax Cost of Debt | 2.34% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 5.901 |
| Total Debt | 659.62 |
| Total Equity | 4,309.74 |
| Total Capital | 4,969.36 |
| Debt Weighting | 13.27 |
| Equity Weighting | 86.73 |
| Wacc |
Build Up Free Cash
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - | - | - |
| Tax Rate | 0.00% | 0.00% | 0.00% | 0.00% | -0.16% | -0.03% | -0.03% | -0.03% | -0.03% | -0.03% |
| EBIAT | - | - | - | - | - | - | - | - | - | - |
| Depreciation | - | - | - | - | - | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventories | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | -3.10 | -4.82 | -3.46 | -8.75 | -3.23 | - | - | - | - | - |
| UFCF | - | - | - | - | - | - | - | - | - | - |
| WACC | ||||||||||
| PV UFCF | - | - | - | - | - | |||||
| SUM PV UFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 5.43 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -25.10 |
| Equity Value | - |
| Shares Outstanding | 62.93 |
| Equity Value Per Share | - |